Aktiesnakken — August 2011
-
slide 9. 2 phase 3 om ragweed mødte primært endpoint
-
det er den første succesfulde ragweed ait study i nordamerika
-
3.5m usd for pre-pen skal betales over 2-3år
-
slide 11... we are well on track
-
to meet 2015 targets
-
q and a
-
hahaa så kom houston på
-
præcis
-
Novod spgm om milestones og om det tyske marked
-
milestones er ikke inkluderet fra japan i år
-
men der vil være en ved initiation on clinical studies og ved phase 3
-
we have not seen any changes in market shares....
-
men shrinking market pga. tilskudsbeskæring
-
nyt spgm om regnskabsprincip og indvirkning på 2015 og 1 spgm om Jext
-
ingen effekt på 2015 på guidance.... det her en minor change til guidance.
-
forventer revenue fra jext i 2. halvår.
-
spgm om grazax/fda.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind